Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in Wisconsin: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 287 | 47% |
| 2020 | 0 | 269 | 49% |
| 2021 | 0 | 189 | 53% |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 34 | 3,364−3.4%/yr | −3.4%/yr | 6.41.0× | 3% | 3,770 in 2030+1.9%/yr |
| Cholecystectomy & appendectomy |
Breast reconstruction in every state, and its device makers · Every procedure market in Wisconsin · Every state · Compare with Illinois
| 2024 |
| 200 |
| 61% |
| 2025 est. | ≈ 200 | – |
| 2026 est. | ≈ 200 | – |
| 2022 | 0 | 208 | 56% |
| 2023 | 0 | 176 | 59% |
| 2024 | 0 | 200 | 61% |
| 2025 from claims | – | 196 158–230 | 61% |
| 2026 forecast | – | 203 159–255 | 61% |
| 2027 forecast | – | 205 152–271 | 61% |
| 2028 forecast | – | 207 147–286 | 61% |
| 2029 forecast | – | 210 143–301 | 62% |
| 2030 forecast | – | 212 139–315 | 62% |
In 2025, 100% hospital outpatient.
| −2.5%/yr |
| 0.4 |
| 0% |
| 380 in 2030−3.5%/yr |
| Michigan | 1 | 303−11%/yr | −11%/yr | 0.4 | 0% | 190 in 2030−7.5%/yr |
| Missouri | 1 | 273−7.1%/yr | −7.1%/yr | 0.4 | 0% | 200 in 2030−4.9%/yr |
| Indiana | 0 | 272−5%/yr | −5%/yr | 0.4 | 23% | 190 in 2030−6.1%/yr |
| Minnesota | 1 | 226−8.1%/yr | −8.1%/yr | 0.5 | 16% | 310 in 2030+5.1%/yr |
| Kansas | 0 | 213−7.1%/yr | −7.1%/yr | 0.5 | 39% | 160 in 2030−4.9%/yr |
| Iowa | 0 | 141−3.2%/yr | −3.2%/yr | 0.3 | 0% | 120 in 2030−3%/yr |
| South Dakota | 0 | 114−2.1%/yr | −2.1%/yr | 0.9 | 0% | 130 in 2030+1.9%/yr |
| 20 |
| 2,445−4.2%/yr |
| −4.2%/yr |
| 4.51.0× |
| 1% |
| 2,580 in 2030+0.9%/yr |
| Colorectal resection | 1 | 955−4%/yr | −4%/yr | 1.71.0× | 0% | 1,070 in 2030+1.9%/yr |
| Antireflux & hiatal hernia surgery | 6 | 452−0.5%/yr | −0.5%/yr | 0.81.0× | 0% | 590 in 2030+4.6%/yr |
| Bariatric surgery | 3 | 135−2.7%/yr | −2.7%/yr | 0.21.2× | 0% | 100 in 2030−4.4%/yr |
No metro breakdown yet.
Johnson & Johnson MedTech leads with 31% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 7 companies reported engagement with Wisconsin’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.